Type Société Anonyme Website www.flamel.com Founded 1990 | Traded as NASDAQ: FLML Headquarters Republic of Ireland | |
 | ||
Industry Healthcare – Drug Delivery Key people Michael S. Anderson (CEO, Director)
Sian Crouzet ( Principal Financial Officer and Financial Controller )
Raphael Jorda Ph.D. ( Chief Operating Officer) (31 December 2005) Revenue 22.44 million USD (Dec31, 2013) Subsidiaries Flamel Technologies, Inc. | ||
Flamel technologies s a flml financial and strategic swot a
Flamel Technologies SA (NASDAQ:FLML), a specialty pharmaceutical company, was set up in 1990 and now is based in Lyon, France. The company sells therapeutic products under GMP guidelines - audited by the United States Food and Drug Administration (FDA) - through its own drug pipeline platforms, Medusa and Micropump. FDA-audited GMP guidelines in France and United States.
Contents
- Flamel technologies s a flml financial and strategic swot a
- Operations
- Research and development
- Products and services
- References
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
The company later acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc. on 8 February 2016.
On 3 January 2017, Flamel, Éclat , and FCS Pediatrics became Avadel Pharmaceuticals plc (NASDAQ:AVDL) in a cross-border merger.
Operations
Flamel Technologies has a strong partnership with GlaxoSmithKline.
In June 2013, Flamel Technologies reached a multi-year partnership agreement with an undisclosed pharmaceutical company, estimating a revenue of over $4 million over the next several years.
In May 2013, Flamel Technologies regained the operating right of two drugs using Trigger Lock® delivery technology.
In 1997, the company completed its acquisition of a pharmaceutical production facility located in Bordeaux, France from SmithKline Beecham (SB), and entered into a production agreement with SB.
Research and development
In September 2013, the US FDA accepted the review of the Flamel Technologies 's second new drug application (NDA) by 28 April 2014 (Prescription Drug User Fee Act (PDUFA) date.
In June 2013, FDA approved the company's Bloxiverz (neostigmine methylsulfate, used for the reversal of the effects of non-depolarizing neuromuscular blocking agents.
In Feb 2013, Flamel Technologies invested a USD$15 million debt financing with Deerfield Management for the company’s R&D projects. The interest rate on the debt was 12.5% and the debt must be repaid over four years. Deerfield Management would also receive a 1.75% royalty on net sales of the project by former Éclat Pharmaceuticals.
Products and services
Flamel Technologies SA produces Micropump-based microparticles (oral drugs), liquid formulations (LiquiTime) and Hycet® (hydrocodone acetaminophen oral solution), and abuse-deterrent formulations (Trigger Lock) drug delivery platforms. Its Medusa is based on a hydrophilic biodegradable polyglutamate chain grafted with hydrophobic Vitamin E. Its DeliVax improves antigen persistence. Its Trigger Lock is used for tamper resistant formulations of narcotics, as well as resistant to alcohol-induced dose dumping.